Why do we need observational studies of everyday patients in the real-life setting?: Table 1
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Randomized controlled trials (RCTs) are performed with the primary goal of understanding the safety and efficacy of a new therapy in a selected group of patients. Even when evidence from these studies strongly favours a new therapy, its role in routine clinical practice may be unclear because of the considerable differences between its efficacy (in clinical trials) and its effectiveness (in the real-life setting). Real-life studies are observational studies that are essential to document benefits and harms of therapy in a wider population and to determine whether patients in routine practice are achieving expected outcomes. In the first article of this supplement, we discuss the relative strengths and limitations of RCTs and real-life studies and explore the current and potential uses of real-life studies in the field of thrombosis, including identifying new safety signals, assessing outcomes in special populations and raising questions about factors affecting medication adherence and persistence. Real-life studies provide a bridge from the results of RCTs to daily clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215 · cited 1×
“1).(7,8) In contrast, patients enrolled in ROCKET-AF were the oldest (median age: 73 years), compared with ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–TIMI 48; median age: 72 years), RE-LY (mean age: 71 years) and ARISTOTLE (median age: 70 years).”
ResultRivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220
Medication Adherence: Its Importance in Cardiovascular Outcomes
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009) · Circulation · doi:10.1161/circulationaha.108.768986 · Cited by 1,488 · cited 2×
“Medication adherence is a growing concern to stakeholders such as payors, healthcare systems, and clinicians due to the association between high levels of non-adherence, adverse outcomes, and high care costs.(50) Rates of non-adherence for VKAs have been reported in the range of 20–61%, with durations of follow-up ran…”
BackgroundOlesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Self-citationStroke and bleeding in atrial fibrillation with chronic kidney disease
Olesen, J. B., Lip, G. Y. H., Kamper, A.-L., Hommel, K., Køber, L., Lane, D. A., Lindhardsen, J., Gislason, G. H., & Torp-Pedersen, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105594 · Cited by 930
Self-citation
Cited by
Corona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0480-2 · Cited by 185
Traish, A. M., Haider, A., Haider, K. S., Doros, G., & Saad, F. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417691136 · Cited by 130
Re‐inventing the randomized controlled trial in medical oncology: The registry‐based trial
Foroughi, S., Wong, H., Gately, L., Lee, M., Simons, K., Tie, J., Burgess, A. W., & Gibbs, P. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12992 · Cited by 43
Dyer, N. L., Surdam, J., & Dusek, J. A. (2022) · Pain Medicine · doi:10.1093/pm/pnab151 · Cited by 23
Metadata
- Authors
- Cohen, A. T., Goto, S., Schreiber, K., & Torp-Pedersen, C.
- Venue
- European Heart Journal Supplements
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07
- Volume
- 17
- Issue
- suppl D
- Pages
- D2-D8
- ISSN
- 1520-765X (ISSN-L)
- 1554-2815
- OpenAlex
- W2137991831
- Cited by
- 125
- References
- 12
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why do we need observational studies of everyday patients in the real-life setting?: Table 1. https://app.cochat.ai/papers/10.1093/eurheartj/suv035
- The paper
- Cohen, A. T., Goto, S., Schreiber, K., & Torp-Pedersen, C. (2015). Why do we need observational studies of everyday patients in the real-life setting?: Table 1. European Heart Journal Supplements. https://doi.org/10.1093/eurheartj/suv035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.